Physician profile
Stuart Mcdonald
NPI 1518951151
$4,134.90
in general payments reported to CMS, 2019-2025
42 companies · $488 in 2025
The $488 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $961 · 2020: $456 · 2021: $372 · 2022: $665 · 2023: $649 · 2024: $543 · 2025: $488.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,601 · Education: $78.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,601.02 |
| Education | $78.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $534.31 | 2019-2025 | Andexxa, Tezspire, Saphnelo |
| Glaxosmithkline, LLC. | $429.47 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $310.06 | 2019-2025 | Ofev |
| Shionogi INC | $279.65 | 2020-2024 | Fetroja |
| Advanced Respiratory, INC | $221.85 | 2019-2021 | |
| Mylan Specialty L.P. | $218.82 | 2019-2024 | Yupelri, Tobi Podhaler |
| Actelion Pharmaceuticals US, INC. | $183.15 | 2020-2025 | Uptravi, Opsumit |
| Novartis Pharmaceuticals Corporation | $167.32 | 2019-2024 | |
| Abiomed | $157.20 | 2023-2025 | Impella |
| Insmed, INC. | $151.30 | 2019-2025 | Arikayce |
| Merck Sharp & Dohme LLC | $139.96 | 2019-2025 | Winrevair, Dificid, Zerbaxa |
| Grifols USA, LLC | $127.57 | 2020-2024 | Prolastin-C Liquid |
| Baxter Healthcare | $93.79 | 2022-2024 | Hillrom - Life 2000 Ventilation System, Hillrom - Vest System Model 105 Home Care |
| Amgen INC. | $86.21 | 2022-2024 | Tezspire |
| Jazz Pharmaceuticals INC. | $85.30 | 2019-2022 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stuart Mcdonald listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.